Dr Natalia Neparidze speaks to ecancer at ASCO 2024 about results from a single-arm phase Ib/II study of immune combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory multiple myeloma.

She reports that the preliminary safety profile of this combination is favourable as ocular toxicity appears in 40% of patients, a score that is not considered high.

Dr Neparidze also reports that preliminary efficacy results showed that 40% of patients achieved a partial response while another 30% developed stable disease.